ByPlus randomized controlled trial: what have we learnt from cancer surgery?

DJ Pournaras PhD, FRCS

North Bristol Centre for Weight Loss, Metabolic and Bariatric Surgery Southmead Hospital Bristol

Twitter: @DJPournaras



Disclosure: conflict of interest

- **Ethicon**
- **Medtronic**
- □ Olympus
- Novo Nordisk
- □ Eli Lilly
- **GSK**
- **⊢ Keyron**
- **□ GI Dynamics**

Disclosure: conflict of interest

Surgeon

André Gide

André Gide

"Everything's already been said, but since nobody was listening, we have to start again."

Clarity of intent

Indication

- Preoperative weight reduction
- Weight regain
- Return of obesity associated disase/diabetes
- Continued postoperatively to improve glycaemic control/promote weight loss maintenance

- Clarity of intent
- Uncompromising high quality of all modalities

- Clarity of intent
- Uncompromising high quality of all modalities
- Do the studies!

Then do it like the obesity experts

ByPlus

Sudlow A, Miras AD, Cohen RV et al. BMJ Open. 2022 Jul 25;12(7):e054313.

ByPlus


 RCT: surgery + intensive goal directed medical therapy OR surgery + standard medical care

ByPlus

RCT: surgery + intensive goal directed medical therapy OR surgery + standard medical care

Endpoint 1: 1 year HbA1c<6.5%</p>

Endpoint 2: 5 years HbA1c<6.5%, BP<130/80 and LDL <2.6mmol/L



Take home messages

- Learn from oncology
- Do the studies

Acknowledgements

- North Bristol
 - Jim Hewes
 - James Hopkins
 - Alan Osborne
 - Alexis Sudlow
 - Simon Phillips
 - Karen Coulman
 - Jessica Munafo
- Imperial College London
 - Prof Alex Miras
 - Prof Steve Bloom
- Karolinska InstitutetStockholm
 - Anders Torell

- University College Dublin
 - Prof Carel le Roux
 - Prof Helen Heneghan
 - Naomi Fearon
 - Jessica Maddock
 - Therese Coleman
 - Finian Fallon
- Oswaldo Cruz German Hospital, São Paulo, Brazil
 - Ricardo Cohen
- Musgrove Hospital, Taunton
 - Richard Welbourn
 - David Mahon